DexCom (DXCM) Q1 FY26 earnings call

DexCom delivered a strong Q1 FY26, marked by robust global revenue growth and record new patient additions, fueled by the successful launch of G7 15 Day and expanded international access. The company demonstrated significant operational efficiency, leading to improved margins and raised full-year operating profit guidance, despite external cost pressures. Management remains focused on broadening CGM access for all diabetes populations, with key clinical trial readouts and product enhancements expected to drive future growth.